Salt of abt-263 and solid-state forms thereof
AssigneeAbbVie Inc.
InventorsThomas Borchardt, Paul Brackemeyer, Nathaniel Catron, Rodger Henry, Xiaochun Lou, Matthew Ravn, Geoff G.Z. Zhang, Deliang Zhou
Life of this patent
Estimating the term…
Abstract
ABT-263 bis-HCl and crystalline polymorphs thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
Claims26
The compound N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino-3-((trifluoromethyl)sulfonyl)benzenesulfonamide bis-hydrochloride (ABT-263 bis-HCl).
A pharmaceutical composition comprising ABT-263 bis-HCl and one or more pharmaceutically acceptable excipients.
A method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, comprising administering to a subject having the disease a therapeutically effective amount of ABT-263 bis-HCl or a pharmaceutical composition comprising ABT-263 bis-HCl and one or more pharmaceutically acceptable excipients.
Dependencies are inferred from the claim text.